Bud‑E Breakthrough: AI-Powered Cannabis Strain Tool Redefines Medical Access

Today—September 5, 2025—the cannabis delivery platform Upling, guided by counsel from Foley & Lardner LLP, officially launched Bud‑E, an AI-powered cannabis genetics tool that combines patient-reported outcomes, medical history, and options for genetic data to deliver personalized strain recommendations. This innovation signals a turning point in cannabis care from guesswork to precision medicine.

Key Development: Bud‑E Introduces Precision Medicine to Cannabis Delivery

Upling, a high-speed medical cannabis delivery app and the first Black‑owned platform with this model, has launched Bud‑E with legal support from Foley & Lardner LLP, who helped file a provisional patent for the technology.

What sets Bud‑E apart:

• It integrates patient-reported outcomes, medical histories, and even optional genetic data to generate evidence-based strain suggestions tailored to individual patient needs.
• By leveraging these personalized factors, Bud‑E transforms cannabis care into a data-driven, precision-based experience, moving away from the traditional trial-and-error method.

Colin Fraser, Upling’s founder, described Bud‑E as a response to his mother’s struggles with accessing cannabis during cancer treatment, aiming to empower patients with accurate medical guidance instead of leaving them to experiment alone.

Impact & Implications: Medical Access, Equity, and the Power of AI

Medical Cannabis Transitioning to Precision Care

Bud‑E offers patients managing conditions like PTSD, chronic pain, or insomnia a more scientific approach to cannabis selection—reducing risk, improving outcomes, and fostering trust in medical cannabis.

Elevating Accessibility and Inclusivity

As the first cannabis delivery app developed by a Black entrepreneur and focused on equity, Upling’s innovation is more than tech—it’s a step toward health justice. Bud‑E’s role in extending informed access to underserved communities adds a vital equity layer.

Legal Safeguards for Innovation

With Foley & Lardner LLP facilitating the provisional patent, Upling is taking proactive steps to safeguard its intellectual property, positioning Bud‑E for broader commercialization and possible licensing down the line.

Scalability and Smart Health Trends

While currently available in D.C. and Maryland, Bud‑E’s AI-driven system sets the stage for expansion into adult-use markets and frontier technologies like real-time dosage adjustment through integration with wearables.

Market & Regional Context: Where Upling Stands

In jurisdictions like Washington, D.C., and Maryland, where medical cannabis legal frameworks are more established, demand for safer, smarter delivery mechanisms is growing rapidly. Bud‑E positions Upling favorably as customers seek precision and convenience. Compared to industry players that focus on automation or e-commerce personalization only, Upling is pioneering medically informed choice—giving it a unique competitive edge.

On a broader scale, Bud‑E reflects shifting consumer expectations across health and wellness sectors, where AI-driven personalization is increasingly seen as standard care. It also underscores Upling’s mission to deliver equity—by offering underserved communities scientific guidance instead of leaving them to rely on guesswork.

Looking Ahead: What’s Next for Bud‑E and Cannabis AI?

• October 2025 Full Launch: Bud‑E is scheduled for full deployment next month across Upling’s service footprint.
• Geographic Expansion: Watch for expansion into adult-use markets and broader state coverage.
• Tech Enhancements: Plans may include AI accuracy improvements, integration with health data systems, and potentially wearables for dosage customization.
• Equity Focus: Upling is likely to continue prioritizing underserved and justice-impacted communities in hiring, service delivery, and platform design.